{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:34:08Z","timestamp":1790303648197,"version":"4.1.0"},"reference-count":236,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.bbcan.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T18:25:06Z","timestamp":1556303106000},"page":"434-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer"],"prefix":"10.1016","volume":"1871","author":[{"given":"Patrycja","family":"Nowak-Sliwinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Scapozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Ruiz i Altaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7270","key":"10.1016\/j.bbcan.2019.04.005_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/462167a","article-title":"Drug discovery: predicting promiscuity","volume":"462","author":"Hopkins","year":"2009","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2017.69","article-title":"Scientific advice \u2013 is drug repurposing missing a trick?","volume":"14","author":"Pantziarka","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0020","doi-asserted-by":"crossref","first-page":"170029","DOI":"10.1038\/sdata.2017.29","article-title":"A standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci. Data"},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt0712-571a","article-title":"NCATS launches drug repurposing program","volume":"30","author":"Allison","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0030","author":"European Commission"},{"issue":"Database issue","key":"10.1016\/j.bbcan.2019.04.005_bb0035","article-title":"DrugBank 3.0: a comprehensive resource for 'omics' research on drugs","volume":"39","author":"Knox","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","article-title":"Aspirin non-responder status in patients with recurrent cerebral ischemic attacks","volume":"250","author":"Grundmann","year":"2003","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.04.023","article-title":"Dosing frequency of aspirin and prevention of heart attacks and strokes","volume":"120","author":"Amory","year":"2007","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0050","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1969.03160070046011","article-title":"Amantadine in the treatment of Parkinson's disease","volume":"208","author":"Schwab","year":"1969","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/15622975.2014.989261","article-title":"Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy","volume":"16","author":"Moller","year":"2015","journal-title":"World J. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0060","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1139\/h2012-068","article-title":"Alterations in energy balance following exenatide administration","volume":"37","author":"Bradley","year":"2012","journal-title":"Appl. Physiol. Nutr. Metab."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/ern.12.43","article-title":"New and emerging treatments for Alzheimer's disease","volume":"12","author":"Corbett","year":"2012","journal-title":"Expert. Rev. Neurother."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/JCP.0b013e318172b49e","article-title":"Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study","volume":"28","author":"George","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5 Suppl 93","key":"10.1016\/j.bbcan.2019.04.005_bb0075","first-page":"S94","article-title":"The role of methotrexate in psoriatic arthritis: what is the evidence?","volume":"33","author":"Ianculescu","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0080","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","article-title":"Rapid reversal of psychotic depression using mifepristone","volume":"21","author":"Belanoff","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.amjcard.2003.09.030","article-title":"Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease","volume":"93","author":"DeBusk","year":"2004","journal-title":"Am. J. Cardiol."},{"issue":"21","key":"10.1016\/j.bbcan.2019.04.005_bb0090","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"8481","key":"10.1016\/j.bbcan.2019.04.005_bb0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(86)92808-4","article-title":"Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III\/LAV replication, to patients with AIDS or AIDS-related complex","volume":"1","author":"Yarchoan","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0100","series-title":"Polypharmacology in Drug Discovery","author":"Car","year":"2012"},{"issue":"66","key":"10.1016\/j.bbcan.2019.04.005_bb0105","doi-asserted-by":"crossref","first-page":"8177","DOI":"10.1039\/c2cc33415a","article-title":"Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases","volume":"48","author":"Winum","year":"2012","journal-title":"Chem. Commun. (Camb.)"},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0110","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-016-0462-4","article-title":"Patient-derived xenografts: a relevant preclinical model for drug development","volume":"35","author":"Pompili","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molmed.2017.02.007","article-title":"Disease modeling in stem cell-derived 3D organoid systems","volume":"23","author":"Dutta","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0130","series-title":"Cancer World","article-title":"Too affordable: how can we overcome the drug repurposing paradox?","author":"Gedes","year":"2016"},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0135","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0140","article-title":"The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies","volume":"6","author":"Ismail","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0145","series-title":"World's Largest Collection of Deprioritised Pharma Compounds Opens to Researchers","author":"MRC","year":"2014"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0150","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0155","first-page":"105","article-title":"Epidemiology of colorectal cancer","volume":"7","author":"Marley","year":"2016","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0160","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","article-title":"Colorectal cancer","volume":"1","author":"Kuipers","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases \u2013 a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.769","article-title":"Concise review: cancer stem cells and minimal residual disease","volume":"30","author":"Ghiaur","year":"2012","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","article-title":"Clinical application of pharmacogenetics","volume":"7","author":"Spear","year":"2001","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0180","doi-asserted-by":"crossref","first-page":"11743","DOI":"10.1038\/ncomms11743","article-title":"A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC","volume":"7","author":"Schell","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0185","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2019.04.005_bb0195","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2019.04.005_bb0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9209","key":"10.1016\/j.bbcan.2019.04.005_bb0205","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.bbcan.2019.04.005_bb0210","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0215","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1186\/1471-2407-14-865","article-title":"Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)","volume":"14","author":"Fernandez-Plana","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0220","first-page":"1","article-title":"An update on the current and emerging targeted agents in metastatic colorectal cancer","volume":"11","author":"Chu","year":"2012","journal-title":"Clin. Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11523-013-0281-x","article-title":"Role of targeted agents in metastatic colorectal cancer","volume":"8","author":"Prenen","year":"2013","journal-title":"Target. Oncol."},{"issue":"9783","key":"10.1016\/j.bbcan.2019.04.005_bb0230","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2016.02.002","article-title":"Role of the tumor stroma in resistance to anti-angiogenic therapy","volume":"25","author":"Huijbers","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to anti-angiogenic therapy","volume":"67","author":"van Beijnum","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors","volume":"8","author":"Rimkus","year":"2016","journal-title":"Cancers"},{"issue":"6 Suppl","key":"10.1016\/j.bbcan.2019.04.005_bb0250","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P","article-title":"Genetic alterations in the adenoma--carcinoma sequence","volume":"70","author":"Cho","year":"1992","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0255","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1513581","article-title":"Colorectal adenomas","volume":"374","author":"Strum","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0260","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.30458","article-title":"Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam","volume":"140","author":"Ertem","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0265","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.50.6.857","article-title":"A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis","volume":"50","author":"Phillips","year":"2002","journal-title":"Gut"},{"issue":"26","key":"10.1016\/j.bbcan.2019.04.005_bb0270","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0275","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1056\/NEJMoa071841","article-title":"Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer","volume":"357","author":"Kerr","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0280","article-title":"Phase 2 trial of metformin combined with 5-fluorouracil in patients with refractory metastatic colorectal cancer","volume":"15","author":"Miranda","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0285","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0290","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/cam4.306","article-title":"Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study","volume":"3","author":"Cardel","year":"2014","journal-title":"Cancer Med."},{"issue":"18","key":"10.1016\/j.bbcan.2019.04.005_bb0295","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","article-title":"Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis","volume":"328","author":"Giardiello","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0300","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13063-016-1744-z","article-title":"ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial","volume":"18","author":"Drew","year":"2017","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.bbcan.2019.04.005_bb0310","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer","volume":"348","author":"Sandler","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13046-015-0199-5","article-title":"Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements","volume":"34","author":"Diaz-Carballo","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0320","series-title":"Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, PA","article-title":"Repurposing disulfiram as a potential novel treatment of drug-resistant metastatic colorectal cancer [abstract]","author":"Stenvang","year":"2018"},{"issue":"7684","key":"10.1016\/j.bbcan.2019.04.005_bb0325","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/emmm.201000098","article-title":"Loss of WNT-TCF addiction and enhancement of HH-GLI1 signalling define the metastatic transition of human colon carcinomas","volume":"2","author":"Varnat","year":"2010","journal-title":"EMBO Mol. Med."},{"issue":"3B","key":"10.1016\/j.bbcan.2019.04.005_bb0335","first-page":"2303","article-title":"The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma","volume":"23","author":"Falkowski","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0340","first-page":"610","article-title":"Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012715","article-title":"Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity","volume":"5","author":"Mayorek","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0350","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bjc.2012.322","article-title":"Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice","volume":"107","author":"Edrei","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10585-014-9635-8","article-title":"Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver","volume":"31","author":"Koh","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000330169","article-title":"Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells","volume":"78","author":"Luo","year":"2011","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0365","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","article-title":"Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases","volume":"22","author":"Neo","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0370","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdw060","article-title":"Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer","volume":"27","author":"Jones","year":"2016","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2019.04.005_bb0375","first-page":"4176","article-title":"Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis","volume":"62","author":"Miyajima","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0380","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12885-016-2157-9","article-title":"Combination of metformin and 5-aminosalicylic acid cooperates to decrease proliferation and induce apoptosis in colorectal cancer cell lines","volume":"16","author":"Saber","year":"2016","journal-title":"BMC Cancer"},{"issue":"8618","key":"10.1016\/j.bbcan.2019.04.005_bb0385","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0140-6736(88)90743-X","article-title":"Effect of cimetidine on survival after gastric cancer","volume":"2","author":"Tonnesen","year":"1988","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0390","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1445-2197.1994.tb04562.x","article-title":"Cimetidine preserves non-specific immune function after colonic resection for cancer","volume":"64","author":"Adams","year":"1994","journal-title":"Aust. N. Z. J. Surg."},{"issue":"8967","key":"10.1016\/j.bbcan.2019.04.005_bb0395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0140-6736(95)92136-2","article-title":"Cimetidine and survival with colorectal cancer","volume":"346","author":"Matsumoto","year":"1995","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150697","article-title":"Metastases and colon cancer tumor growth display divergent responses to modulation of canonical WNT signaling","volume":"11","author":"Seth","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0405","doi-asserted-by":"crossref","first-page":"882","DOI":"10.15252\/emmm.201303799","article-title":"A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12","volume":"6","author":"Duquet","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12885-016-2124-5","article-title":"A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification","volume":"16","author":"Tarpgaard","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0415","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00176826","article-title":"Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC)","volume":"3","author":"Holdener","year":"1985","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0420","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2016.05.027","article-title":"Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis","volume":"33","author":"Rokkas","year":"2016","journal-title":"European J. Int. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086299","article-title":"Functional Module Connectivity Map (FMCM): a framework for searching repurposed drug compounds for systems treatment of cancer and an application to colorectal adenocarcinoma","volume":"9","author":"Chung","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0435","doi-asserted-by":"crossref","first-page":"16027","DOI":"10.1038\/cddiscovery.2016.27","article-title":"Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer","volume":"2","author":"Hsieh","year":"2016","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0440","first-page":"2573","article-title":"Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors","volume":"7","author":"Guilbaud","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0445","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10689-016-9901-9","article-title":"Chemoprevention of familial adenomatous polyposis","volume":"15","author":"Lynch","year":"2016","journal-title":"Familial Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0450","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0455","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/gutjnl-2014-307235","article-title":"An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis","volume":"65","author":"Lynch","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0460","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/1055-9965.EPI-11-0992-T","article-title":"Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis","volume":"21","author":"Bodmer","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0465","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pds.3823","article-title":"No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK","volume":"24","author":"Kowall","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0470","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0475","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1055-9965.EPI-17-0424","article-title":"A Cohort study of metformin and colorectal cancer risk among patients with diabetes mellitus","volume":"27","author":"Bradley","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0480","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fendo.2018.00622","article-title":"Metformin and colorectal cancer","volume":"9","author":"Higurashi","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0485","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1349-7006.2008.00933.x","article-title":"Metformin suppresses intestinal polyp growth in ApcMin\/+ mice","volume":"99","author":"Tomimoto","year":"2008","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0490","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mc.20637","article-title":"Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase","volume":"49","author":"Hosono","year":"2010","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0495","doi-asserted-by":"crossref","first-page":"100","DOI":"10.20892\/j.issn.2095-3941.2016.0088","article-title":"Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats","volume":"14","author":"Bekusova","year":"2017","journal-title":"Cancer Biol. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0500","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1940-6207.CAPR-10-0186","article-title":"Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial","volume":"3","author":"Hosono","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0505","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","article-title":"High and typical 18F-FDG bowel uptake in patients treated with metformin","volume":"35","author":"Gontier","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0510","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2407-12-118","article-title":"Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial","volume":"12","author":"Higurashi","year":"2012","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2019.04.005_bb0515","first-page":"1547","article-title":"Risk of duodenal cancer in patients with familial adenomatous polyposis","volume":"53","author":"Biasco","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0520","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gut.2003.027771","article-title":"Duodenal adenomatosis in familial adenomatous polyposis","volume":"53","author":"Bulow","year":"2004","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0525","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/bjs.1800801244","article-title":"Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis","volume":"80","author":"Nugent","year":"1993","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0530","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/bjs.1800831232","article-title":"Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis","volume":"83","author":"Seow-Choen","year":"1996","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0535","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2016.2522","article-title":"Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial","volume":"315","author":"Samadder","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0540","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","author":"Meyskens","year":"2008","journal-title":"Cancer Prev. Res."},{"issue":"6917","key":"10.1016\/j.bbcan.2019.04.005_bb0545","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0550","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5A","key":"10.1016\/j.bbcan.2019.04.005_bb0555","first-page":"3147","article-title":"Non-steroidal anti-inflammatory drugs in cancer prevention and therapy","volume":"27","author":"Guadagni","year":"2007","journal-title":"Anticancer Res."},{"issue":"9754","key":"10.1016\/j.bbcan.2019.04.005_bb0560","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0565","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12885-017-3757-8","article-title":"Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials","volume":"17","author":"Veettil","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0570","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0575","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrmicro2783","article-title":"Studies of endogenous retroviruses reveal a continuing evolutionary saga","volume":"10","author":"Stoye","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0580","doi-asserted-by":"crossref","first-page":"9173","DOI":"10.3390\/ijms15069173","article-title":"Expression of human endogenous retrovirus env genes in the blood of breast cancer patients","volume":"15","author":"Rhyu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0585","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ijc.28389","article-title":"Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer","volume":"134","author":"Wang-Johanning","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0590","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jclinpath-2013-202089","article-title":"Elevation of human ERV3-1 env protein expression in colorectal cancer","volume":"67","author":"Lee","year":"2014","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029950","article-title":"Expression patterns of non-coding spliced transcripts from human endogenous retrovirus HERV-H elements in colon cancer","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"issue":"34","key":"10.1016\/j.bbcan.2019.04.005_bb0600","doi-asserted-by":"crossref","first-page":"12426","DOI":"10.1073\/pnas.1413299111","article-title":"Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential","volume":"111","author":"Ohnuki","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0605","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/ijmm.2015.2289","article-title":"Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro","volume":"36","author":"Lan","year":"2015","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0610","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1086\/318452","article-title":"Treatment of potentially life-threatening enterovirus infections with pleconaril","volume":"32","author":"Rotbart","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0615","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/1078-0432.CCR-1576-03","article-title":"Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis","volume":"10","author":"Yamamoto","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2019.04.005_bb0620","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.15252\/emmm.201404084","article-title":"The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer","volume":"6","author":"Melotti","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0625","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, 'wonder drug' from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0630","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/138920112800399095","article-title":"History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents","volume":"13","author":"Campbell","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0635","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin \u2013 old drug, new tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol."},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001883","article-title":"Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (\u2013\/\u2013) mice and effects on mammalian GABA(A) channel activity","volume":"6","author":"Menez","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0645","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tips.2012.05.002","article-title":"Ivermectin binding sites in human and invertebrate Cys-loop receptors","volume":"33","author":"Lynagh","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0650","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00228-015-1832-0","article-title":"Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide","volume":"71","author":"Tamargo","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0655","article-title":"Criteria and evidence to assess actual or potential bioequiv-alence problems","volume":"5","author":"C. Code of Federal Register 21","year":"2017","journal-title":"Code Federal Regul."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0660","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2344\/0003-3006(2007)54[19:DTIDPG]2.0.CO;2","article-title":"Drug therapy in dental practice: general principles. Part 2 \u2013 pharmacodynamic considerations","volume":"54","author":"Becker","year":"2007","journal-title":"Anesth. Prog."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0665","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/jvp.12390","article-title":"Establishment of a cell line for assessing drugs as canine P-glycoprotein substrates: proof of principle","volume":"40","author":"Mealey","year":"2017","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0670","series-title":"Report 2 of the Council on Science and Public Health (A-04). Impact of Drug Formularies and Therapeutic Interchange on Health Outcomes","author":"American Medical Association","year":"2004"},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0675","first-page":"1625","article-title":"The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan","volume":"57","author":"Seed","year":"1997","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0680","doi-asserted-by":"crossref","first-page":"18456","DOI":"10.18632\/oncotarget.14472","article-title":"2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications","volume":"8","author":"Gonzalez","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb0685","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0690","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1038\/ncomms8138","article-title":"Genome-wide association study of colorectal cancer identifies six new susceptibility loci","volume":"6","author":"Schumacher","year":"2015","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0695","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5306\/wjco.v3.i12.150","article-title":"Multiple roles of angiotensin in colorectal cancer","volume":"3","author":"Kuniyasu","year":"2012","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0700","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","article-title":"Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer","volume":"2","author":"Escobar","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0705","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000362092","article-title":"Role of two types of angiotensin II receptors in colorectal carcinoma progression","volume":"81","author":"Zhou","year":"2014","journal-title":"Pathobiology"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0710","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3109\/00365529009091915","article-title":"Mesalazine: a global safety evaluation","volume":"172","author":"Brimblecombe","year":"1990","journal-title":"Scand. J. Gastroenterol. Suppl."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0715","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/carcin\/24.3.443","article-title":"Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells","volume":"24","author":"Reinacher-Schick","year":"2003","journal-title":"Carcinogenesis"},{"issue":"15","key":"10.1016\/j.bbcan.2019.04.005_bb0720","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.ejca.2006.03.030","article-title":"5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death","volume":"42","author":"Fina","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0725","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/carcin\/bgl071","article-title":"Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt\/beta-catenin pathway activity","volume":"27","author":"Bos","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0730","doi-asserted-by":"crossref","first-page":"980458","DOI":"10.1155\/2012\/980458","article-title":"Colorectal cancer chemoprevention by mesalazine and its derivatives","volume":"2012","author":"Stolfi","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0735","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"14","key":"10.1016\/j.bbcan.2019.04.005_bb0740","first-page":"3978","article-title":"Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0745","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/110241599750007838","article-title":"Local inflammatory peritoneal response to operative trauma: studies on cell activity, cytokine expression, and adhesion molecules","volume":"165","author":"Sendt","year":"1999","journal-title":"Eur. J. Surg."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0750","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600048","article-title":"Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells","volume":"86","author":"Matsumoto","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10010026","article-title":"Colorectal cancers: an update on their molecular pathology","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0760","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"issue":"5670","key":"10.1016\/j.bbcan.2019.04.005_bb0765","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.bbcan.2019.04.005_bb0770","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6-7","key":"10.1016\/j.bbcan.2019.04.005_bb0775","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/emmm.200900039","article-title":"Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion","volume":"1","author":"Varnat","year":"2009","journal-title":"EMBO Mol. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2019.04.005_bb0780","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1073\/pnas.0700776104","article-title":"Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK\/AKT pathways","volume":"104","author":"Stecca","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0785","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0790","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V96.5.1789","article-title":"Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions","volume":"96","author":"McCarty","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb0795","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/0008-5472.CAN-07-0426","article-title":"Myc goes global: new tricks for an old oncogene","volume":"67","author":"Knoepfler","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0800","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12967-016-1031-5","article-title":"Repurposing of approved cardiovascular drugs","volume":"14","author":"Ishida","year":"2016","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0805","doi-asserted-by":"crossref","first-page":"C176","DOI":"10.1152\/ajpcell.00196.2016","article-title":"Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC","volume":"312","author":"Mitrugno","year":"2017","journal-title":"Am. J. Phys. Cell Physiol."},{"issue":"6127","key":"10.1016\/j.bbcan.2019.04.005_bb0810","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"5853","key":"10.1016\/j.bbcan.2019.04.005_bb0815","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscapes of human breast and colorectal cancers","volume":"318","author":"Wood","year":"2007","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0820","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.onc.1204123","article-title":"The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin\/TCF-4 signaling","volume":"20","author":"Dihlmann","year":"2001","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0825","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2165\/00003495-199345050-00011","article-title":"Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy","volume":"45","author":"Plosker","year":"1993","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0830","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M15-3016","article-title":"Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in diabetes","volume":"164","author":"Chamberlain","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0835","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb0840","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/onc.2012.181","article-title":"Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects","volume":"32","author":"Pierotti","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0845","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1940-6207.CAPR-08-0081","article-title":"The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase","volume":"1","author":"Zakikhani","year":"2008","journal-title":"Cancer Prev. Res."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2019.04.005_bb0850","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e14521","article-title":"Impact of metformin on survival in patients with type II diabetes and metastatic colorectal cancer","volume":"33","author":"He","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0855","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.01.057","article-title":"Primary prevention of colorectal cancer","volume":"138","author":"Chan","year":"2010","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0860","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/j.1572-0241.2006.00725.x","article-title":"Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study","volume":"101","author":"Limburg","year":"2006","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0865","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/gut.2005.073163","article-title":"Influence of obesity on the risk of developing colon cancer","volume":"55","author":"Frezza","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0870","doi-asserted-by":"crossref","first-page":"40363","DOI":"10.1038\/srep40363","article-title":"Perceived stress and colorectal cancer incidence: the japan collaborative cohort study","volume":"7","author":"Kikuchi","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0875","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2796.2007.01826.x","article-title":"Perceived stress and risk of colorectal cancer in men and women: a prospective cohort study","volume":"263","author":"Nielsen","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0880","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f165","article-title":"Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women","volume":"346","author":"Heikkila","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0885","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ejca.2007.01.027","article-title":"The role of self-reported stress in the development of breast cancer and prostate cancer: a prospective cohort study of employed males and females with 30 years of follow-up","volume":"43","author":"Metcalfe","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0890","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/bjc.2017.496","article-title":"Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank","volume":"118","author":"Morris","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb0895","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.soc.2017.11.002","article-title":"Colon cancer: what we eat","volume":"27","author":"Pan","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"7401","key":"10.1016\/j.bbcan.2019.04.005_bb0900","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature11127","article-title":"Chemical genetic discovery of targets and anti-targets for cancer polypharmacology","volume":"486","author":"Dar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0905","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-pharmtox-010611-134520","article-title":"Systems pharmacology: network analysis to identify multiscale mechanisms of drug action","volume":"52","author":"Zhao","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0910","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/bib\/bbr005","article-title":"Literature mining, ontologies and information visualization for drug repurposing","volume":"12","author":"Andronis","year":"2011","journal-title":"Brief. Bioinform."},{"issue":"9","key":"10.1016\/j.bbcan.2019.04.005_bb0915","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijmedinf.2014.06.009","article-title":"Text mining of cancer-related information: review of current status and future directions","volume":"83","author":"Spasic","year":"2014","journal-title":"Int. J. Med. Inform."},{"issue":"24","key":"10.1016\/j.bbcan.2019.04.005_bb0920","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/bioinformatics\/btx454","article-title":"Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer","volume":"33","author":"Baker","year":"2017","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb0925","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb0930","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/bioinformatics\/btv585","article-title":"Automatic semantic classification of scientific literature according to the hallmarks of cancer","volume":"32","author":"Baker","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0935","first-page":"41","article-title":"Capturing cancer initiating events in OncoCL, a cancer cell ontology","volume":"2014","author":"Dolan","year":"2014","journal-title":"AMIA Jt. Summits Transl. Sci. Proc."},{"issue":"Web Server issue","key":"10.1016\/j.bbcan.2019.04.005_bb0940","article-title":"OncoSearch: cancer gene search engine with literature evidence","volume":"42","author":"Lee","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2019.04.005_bb0945","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3154","article-title":"Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov","volume":"5","author":"Su","year":"2017","journal-title":"PeerJ"},{"issue":"Suppl. 5","key":"10.1016\/j.bbcan.2019.04.005_bb0950","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12859-016-1041-6","article-title":"DrugQuest \u2013 a text mining workflow for drug association discovery","volume":"17","author":"Papanikolaou","year":"2016","journal-title":"BMC Bioinformatics"},{"issue":"5795","key":"10.1016\/j.bbcan.2019.04.005_bb0955","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"33","key":"10.1016\/j.bbcan.2019.04.005_bb0960","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1073\/pnas.1000138107","article-title":"Discovery of drug mode of action and drug repositioning from transcriptional responses","volume":"107","author":"Iorio","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065683","article-title":"ToP: a trend-of-disease-progression procedure works well for identifying cancer genes from multi-state cohort gene expression data for human colorectal cancer","volume":"8","author":"Chung","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.04.005_bb0970","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4939-9151-8_14","article-title":"Studying cancer heterogeneity by single-cell RNA sequencing","volume":"1956","author":"Bagnoli","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2019.04.005_bb0975","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.soc.2009.07.004","article-title":"Genome-wide association studies and colorectal cancer","volume":"18","author":"Le Marchand","year":"2009","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb0980","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng2089","article-title":"Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24","volume":"39","author":"Zanke","year":"2007","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0985","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/gut.2010.215947","article-title":"Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population","volume":"60","author":"Cui","year":"2011","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bbcan.2019.04.005_bb0990","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ng.2985","article-title":"Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat. Genet."},{"issue":"20","key":"10.1016\/j.bbcan.2019.04.005_bb0995","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1158\/0008-5472.CAN-13-3540","article-title":"Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling","volume":"74","author":"van Noort","year":"2014","journal-title":"Cancer Res."},{"issue":"23-24","key":"10.1016\/j.bbcan.2019.04.005_bb1000","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","article-title":"Applications of connectivity map in drug discovery and development","volume":"17","author":"Qu","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb1005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006536","article-title":"Human disease-drug network based on genomic expression profiles","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.bbcan.2019.04.005_bb1010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2019.04.005_bb1020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb1025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.coph.2005.02.001","article-title":"Cardiovascular hazard and non-steroidal anti-inflammatory drugs","volume":"5","author":"Wang","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"issue":"11","key":"10.1016\/j.bbcan.2019.04.005_bb1030","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/tx100186t","article-title":"Protein adducts as prospective biomarkers of nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"issue":"7403","key":"10.1016\/j.bbcan.2019.04.005_bb1035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11159","article-title":"Large-scale prediction and testing of drug activity on side-effect targets","volume":"486","author":"Lounkine","year":"2012","journal-title":"Nature"},{"issue":"7270","key":"10.1016\/j.bbcan.2019.04.005_bb1040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature08506","article-title":"Predicting new molecular targets for known drugs","volume":"462","author":"Keiser","year":"2009","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb1045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028025","article-title":"Systematic drug repositioning based on clinical side-effects","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2019.04.005_bb1050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-62703-435-7_20","article-title":"PharmGKB: the pharmacogenomics knowledge base","volume":"1015","author":"Thorn","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.bbcan.2019.04.005_bb1055","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archinternmed.2011.182","article-title":"A quantitative analysis of adverse events and \"overwarning\" in drug labeling","volume":"171","author":"Duke","year":"2011","journal-title":"Arch. Intern. Med."},{"issue":"5886","key":"10.1016\/j.bbcan.2019.04.005_bb1060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1158140","article-title":"Drug target identification using side-effect similarity","volume":"321","author":"Campillos","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2019.04.005_bb1065","series-title":"Nonlinear System Identification","author":"Nelles","year":"2001"},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb1070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/2472630316682338","article-title":"Current trends in multidrug optimization: an alley of future successful treatment of complex disorders","volume":"22","author":"Weiss","year":"2017","journal-title":"SLAS Technol."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb1075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nprot.2016.017","article-title":"Optimization of drug combinations using Feedback System Control","volume":"11","author":"Nowak-Sliwinska","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1080","series-title":"Differential evolution: A Practical Approach to Global Optimization","author":"Price","year":"2005"},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb1085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10456-015-9462-9","article-title":"Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer","volume":"18","author":"Weiss","year":"2015","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbcan.2019.04.005_bb1090","doi-asserted-by":"crossref","first-page":"43005","DOI":"10.1038\/srep43005","article-title":"Combination of ruthenium(II)-arene complex [Ru(\u02736-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in angiostatic and antitumor activity","volume":"7","author":"Berndsen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1095","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1038\/srep14508","article-title":"A streamlined search technology for identification of synergistic drug combinations","volume":"5","author":"Weiss","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1100","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/msb.2011.26","article-title":"PREDICT: a method for inferring novel drug indications with application to personalized medicine","volume":"7","author":"Gottlieb","year":"2011","journal-title":"Mol. Syst. Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb1105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/nar\/13.2.645","article-title":"The statistical distribution of nucleic acid similarities","volume":"13","author":"Smith","year":"1985","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb1110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-2946-5-30","article-title":"Drug repositioning: a machine-learning approach through data integration","volume":"5","author":"Napolitano","year":"2013","journal-title":"J. Cheminform."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb1115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","article-title":"In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole","volume":"165","author":"Pourgholami","year":"2001","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2019.04.005_bb1120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-009-1157-8","article-title":"Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer","volume":"65","author":"Pourgholami","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1125","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1038\/ncomms5212","article-title":"Human symptoms-disease network","volume":"5","author":"Zhou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0039-7","article-title":"A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection","volume":"4","author":"Langhauser","year":"2018","journal-title":"NPJ Syst. Biol. Appl."},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb1135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41598-017-18315-9","article-title":"Predicting inhibitory and activatory drug targets by chemically and genetically perturbed transcriptome signatures","volume":"8","author":"Sawada","year":"2018","journal-title":"Sci. Rep."},{"issue":"5644","key":"10.1016\/j.bbcan.2019.04.005_bb1140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.1087361","article-title":"A Bayesian networks approach for predicting protein-protein interactions from genomic data","volume":"302","author":"Jansen","year":"2003","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bbcan.2019.04.005_bb1145","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/bioinformatics\/btv080","article-title":"Large-scale exploration and analysis of drug combinations","volume":"31","author":"Li","year":"2015","journal-title":"Bioinformatics"},{"issue":"68","key":"10.1016\/j.bbcan.2019.04.005_bb1150","doi-asserted-by":"crossref","first-page":"33030","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"issue":"70","key":"10.1016\/j.bbcan.2019.04.005_bb1155","doi-asserted-by":"crossref","first-page":"33245","DOI":"10.18632\/oncotarget.26091","article-title":"Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma","volume":"9","author":"Lerario","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bbcan.2019.04.005_bb1160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/etc.3306","article-title":"Nontarget effects of ivermectin residues on earthworms and springtails dwelling beneath dung of treated cattle in four countries","volume":"35","author":"Scheffczyk","year":"2016","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1165","doi-asserted-by":"crossref","first-page":"13912","DOI":"10.1038\/srep13912","article-title":"Low doses of ivermectin cause sensory and locomotor disorders in dung beetles","volume":"5","author":"Verdu","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2019.04.005_bb1170","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00244-017-0480-z","article-title":"Residues of diclofenac in tissues of vultures in India: a post-ban scenario","volume":"74","author":"Nambirajan","year":"2018","journal-title":"Arch. Environ. Contam. Toxicol."},{"key":"10.1016\/j.bbcan.2019.04.005_bb1175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1749-6632.2011.06293.x","article-title":"Dropping dead: causes and consequences of vulture population declines worldwide","volume":"1249","author":"Ogada","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2019.04.005_bb1180","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.chemosphere.2010.08.051","article-title":"Impact of wastewaters and hospital effluents on the occurrence of controlled substances in surface waters","volume":"81","author":"Lin","year":"2010","journal-title":"Chemosphere"},{"issue":"1","key":"10.1016\/j.bbcan.2019.04.005_bb1185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.envint.2011.10.002","article-title":"Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?","volume":"39","author":"Besse","year":"2012","journal-title":"Environ. Int."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X1930037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X1930037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:34:05Z","timestamp":1759638845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X1930037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":236,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0304419X1930037X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2019.04.005","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}